
PRESS RELEASE

<u>BSE: 506690</u>	<u>NSE: UNICHEMLAB</u>	<u>Reuters: UNLB.BO</u>	<u>Bloomberg: UN@IN</u>
---------------------------	-------------------------------	--------------------------------	--------------------------------

Mumbai, October 17, 2012

Unichem Laboratories receives ANDA tentative approval from USFDA for IRBESARTAN TABLETS

Unichem laboratories Limited is pleased to announce that it has received ANDA tentative approval from the United States Food and Drug Administration (U.S. FDA) for Irbesartan. Final approval will be received after the patent expires on Dec 7, 2015.

Irbesartan Tablets 75mg, 150mg and 300mg are therapeutically equivalent to AVAPRO[®] Tablets 75mg, 150mg and 300mg from Sanofi Aventis US, LLC.

Irbesartan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

The product will be commercialized (after the final approval) from Unichem's Ghaziabad plant. Active pharmaceutical ingredient i.e. Irbesartan used for this ANDA is also made in house at Pithampur plant.

The current market size is US\$ 450 Million.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.

More information about the company can be found at www.unichemlabs.com.

Contacts:

Mr. K Subharaman

Mr. Rakesh Parikh

Mr. M Gundu Rao

Tel: +912266888404

Tel: +912266888414

Tel: +912266888380

Cell: +919833031121

Cell: +919892925555

Cell: +919820228944

e-Mail: subharamank@unichemlabs.com rparikh@unichemlabs.com gundurao@unichemlabs.com



This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
